ak 1

AK-1 is a sirtuin 2 (SIRT2) inhibitor (IC50:12.5 µM).that prevents hippocampal neurodegeneration in Alzheimer's disease models and induces cell cycle arrest in colon carcinoma cells.

AK-IN-1, a competitive inhibitor for adenosine (Ado) but not for ATP, demonstrates significant inhibition of AK activity, achieving 86%, 87%, and 89% at concentrations of 2, 4, and 10 µM, respectively. This compound shows promise for research across various disease areas, such as ischemia, inflammation, and seizures.

Ligufalimab (AK 117), a humanized IgG4 monoclonal antibody targeting CD47, does not lead to red blood cell (RBC) hemagglutination but promotes phagocytosis and exhibits anti-tumor activity [1].

Dresbuxelimab (AK-119), an IgG-κ monoclonal antibody, selectively targets CD73 and is commonly produced using a Chinese Hamster Ovary (CHO) cell expression system [1].

AK-42 is a novel potent and specific inhibitor of CLC-2, displaying unprecedented selectivity over CLC-1, the closest CLC-2 homolog, and exhibiting no off-target engagement against a panel of 61 common channels, receptors, and transporters expressed in brain tissue.

ABT-702 hydrochloride effectively inhibits adenosine kinase, exhibiting an IC50 value of 1.7 nM [1] [2].

AK-2292 is a potent and selective STAT5 PROTAC degrader with a DC50 of 0.10 μM. It induces degradation of STAT5A B proteins in vitro and in vivo and can cause tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models [1] [2].

Compound AK-2, also known as hAChE hBACE-1-IN-4, is a quinazoline derivative that demonstrates significant inhibitory activity against the enzymes hAChE and hBACE-1 (hAChE, IC 50 = 0.283 μM; hBACE-1, IC 50 = 0.231 μM). This compound also shows potential in inhibiting Aβ aggregation and possesses characteristics such as non-neurotoxicity, blood-brain barrier permeability, and oral activity, making it a valuable agent for research in Alzheimer's disease [1].